[go: up one dir, main page]

ATE454892T1 - N- (2s)-4-(3,4-difluorobenzyl)morpholin-2-yl methyl -2- 3- (methylsulphonyl)amino phenyl acetamid als ccr3 antagonist für die behandlung von entzündlichen erkrankungen - Google Patents

N- (2s)-4-(3,4-difluorobenzyl)morpholin-2-yl methyl -2- 3- (methylsulphonyl)amino phenyl acetamid als ccr3 antagonist für die behandlung von entzündlichen erkrankungen

Info

Publication number
ATE454892T1
ATE454892T1 AT03712117T AT03712117T ATE454892T1 AT E454892 T1 ATE454892 T1 AT E454892T1 AT 03712117 T AT03712117 T AT 03712117T AT 03712117 T AT03712117 T AT 03712117T AT E454892 T1 ATE454892 T1 AT E454892T1
Authority
AT
Austria
Prior art keywords
methylsulphonyl
difluorobenzyl
morpholine
methyl
treatment
Prior art date
Application number
AT03712117T
Other languages
English (en)
Inventor
Rachael Ancliff
Caroline Cook
Colin Eldred
Paul Gore
Lee Harrison
Martin Hayes
Simon Hodgson
Duncan Judd
Suzanne KEELING
Xiao Lewell
Gail Mills
Graeme Robertson
Stephen Swanson
Andrew Walker
Mark Wilkinson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE454892T1 publication Critical patent/ATE454892T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT03712117T 2002-03-28 2003-03-27 N- (2s)-4-(3,4-difluorobenzyl)morpholin-2-yl methyl -2- 3- (methylsulphonyl)amino phenyl acetamid als ccr3 antagonist für die behandlung von entzündlichen erkrankungen ATE454892T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207449.0A GB0207449D0 (en) 2002-03-28 2002-03-28 Novel compounds
PCT/EP2003/003339 WO2003082291A1 (en) 2002-03-28 2003-03-27 N-{´ (2s) -4- (3, 4-difluorobenzyl) morpholin-2yl!methyl} -2-{3-' (methylsulphonyl) amino! phenyl}acetamide as ccr3 antagonist for the treatment of inflammatory conditions

Publications (1)

Publication Number Publication Date
ATE454892T1 true ATE454892T1 (de) 2010-01-15

Family

ID=9933998

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03712117T ATE454892T1 (de) 2002-03-28 2003-03-27 N- (2s)-4-(3,4-difluorobenzyl)morpholin-2-yl methyl -2- 3- (methylsulphonyl)amino phenyl acetamid als ccr3 antagonist für die behandlung von entzündlichen erkrankungen

Country Status (22)

Country Link
US (1) US20060058299A1 (de)
EP (1) EP1487453B1 (de)
JP (1) JP4490110B2 (de)
KR (1) KR20040095347A (de)
CN (1) CN1642553A (de)
AR (1) AR039177A1 (de)
AT (1) ATE454892T1 (de)
AU (1) AU2003216905A1 (de)
BR (1) BR0308719A (de)
CA (1) CA2479910A1 (de)
DE (1) DE60330952D1 (de)
ES (1) ES2339436T3 (de)
GB (1) GB0207449D0 (de)
IL (1) IL163648A0 (de)
IS (1) IS7415A (de)
MX (1) MXPA04009458A (de)
NO (1) NO20044098L (de)
PL (1) PL372930A1 (de)
RU (1) RU2004126145A (de)
TW (1) TW200400823A (de)
WO (1) WO2003082291A1 (de)
ZA (1) ZA200406990B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
WO2007011292A1 (en) * 2005-07-21 2007-01-25 Astrazeneca Ab N-benzyl-morpholine derivatives as modulators of the chemokine receptor
HUP0500877A2 (en) * 2005-09-22 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
HUP0500886A2 (en) * 2005-09-23 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use
KR20080046209A (ko) * 2005-09-22 2008-05-26 사노피-아벤티스 Ｃｃｒ3 수용체 리간드로서의 신규한 아미노-알킬-아미드 유도체
HUP0800478A2 (en) * 2008-07-31 2010-03-01 Sanofi Aventis Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
JP2015500221A (ja) * 2011-12-01 2015-01-05 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 眼疾患の治療および予防方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562929A (en) * 1979-06-21 1981-01-13 Sumitomo Chem Co Ltd Preparation of optically active cyclopentenolone
CZ284687B6 (cs) * 1986-04-30 1999-02-17 Dainippon Pharmaceutical Co., Ltd. Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
JPH01117882A (ja) * 1987-10-30 1989-05-10 Dainippon Pharmaceut Co Ltd 複素環式カルボン酸アミド誘導体
JPH03291274A (ja) * 1990-04-09 1991-12-20 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
TW223629B (de) * 1992-03-06 1994-05-11 Hoffmann La Roche
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US6031097A (en) * 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
WO2000035877A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
BR0014513A (pt) * 1999-09-14 2002-07-02 Aventis Pharma Inc Derivados de etila e propila insubstituìdos por fenóxi de tienoisoxazol úteis como antagonistas de d4
CN1678594A (zh) * 2000-09-29 2005-10-05 葛兰素集团有限公司 用于治疗炎性疾病的吗啉－乙酰胺衍生物
IL155092A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
EP1487453B1 (de) 2010-01-13
CN1642553A (zh) 2005-07-20
WO2003082291A1 (en) 2003-10-09
TW200400823A (en) 2004-01-16
US20060058299A1 (en) 2006-03-16
ZA200406990B (en) 2005-11-08
BR0308719A (pt) 2005-01-04
AR039177A1 (es) 2005-02-09
JP4490110B2 (ja) 2010-06-23
PL372930A1 (en) 2005-08-08
DE60330952D1 (de) 2010-03-04
ES2339436T3 (es) 2010-05-20
RU2004126145A (ru) 2005-06-27
CA2479910A1 (en) 2003-10-09
KR20040095347A (ko) 2004-11-12
GB0207449D0 (en) 2002-05-08
JP2005525390A (ja) 2005-08-25
IS7415A (is) 2004-08-19
AU2003216905A1 (en) 2003-10-13
IL163648A0 (en) 2005-12-18
MXPA04009458A (es) 2005-07-27
EP1487453A1 (de) 2004-12-22
NO20044098L (no) 2004-10-04

Similar Documents

Publication Publication Date Title
NO20064418L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
EP1513403A4 (de) Herzglykoside für die behandlung von mukoviszidose und anderen il-8-bedingten erkrankungen
ATE535236T1 (de) Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit
DE60316116D1 (de) Amide von aminoalkylsubstituierten azetidinen, pyrrolidinen, piperidinen und azepanen
ATE355293T1 (de) Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
ATE514697T1 (de) 7-ä4-ä2-(2,6-dichloro-4- methylphenoxy)ethoxyüphenylü-3,9- diazabicycloä3.3.1ünon-6-ene-6-carbonsäure- cyclopropyl-(2,3-dimethylbenzyl)amid als renin- hemmer für die behandlung von bluthochdruck
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE381263T1 (de) Fungizide zusammensetzungen, die n-(alpha-cyano-2-thenyl)-4-ethyl-2-ethylamino-5 thiazolcarboxamide enthalten
EA200400280A1 (ru) Новые неочищенные и кристаллические формы гидрохлорида лерканидипина
ATE454892T1 (de) N- (2s)-4-(3,4-difluorobenzyl)morpholin-2-yl methyl -2- 3- (methylsulphonyl)amino phenyl acetamid als ccr3 antagonist für die behandlung von entzündlichen erkrankungen
EP1515722A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
NO20064417L (no) Nye isoamidosubstituertehydroksy-6-fenylfenantridiner
DE60014343D1 (de) N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten
RS52260B (en) N- (2-hydroxyethyl) -N-methyl-4- (quinoline-8-yl (1- (thiazol-4-ylmethyl) piperidin-4-ylidene) methyl) benzamide, a process for its production as well as its use for treatment PAIN, TENSION AND DEPRESSION
DE60307086D1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
ATE420860T1 (de) N-substituierte amide als nk1 rezeptor antagonisten
ATE293591T1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
BR0011330A (pt) 2-aril-1,2,4-triazina-3,5-di(ti)onas substituìdas
ATE411318T1 (de) Immunmodulierende oxopyrazolocinnoline als cd80- inhibitoren
DE50209798D1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol-derivative für die behandlung von migräne
PT1358182E (pt) Derivados de diazocinas e sua utilizacao como inibidores de triptase
DK1421086T3 (da) 2-(Aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl-derivater med antipsykotisk aktivitet

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties